3.01
price up icon0.67%   0.02
after-market 시간 외 거래: 3.00 -0.010 -0.33%
loading
전일 마감가:
$2.99
열려 있는:
$2.99
하루 거래량:
7.24M
Relative Volume:
0.83
시가총액:
$2.66B
수익:
$1.31M
순이익/손실:
$-597.65M
주가수익비율:
-3.1031
EPS:
-0.97
순현금흐름:
$-425.62M
1주 성능:
+6.36%
1개월 성능:
+7.89%
6개월 성능:
-5.05%
1년 성능:
-43.53%
1일 변동 폭
Value
$2.90
$3.065
1주일 범위
Value
$2.64
$3.065
52주 변동 폭
Value
$1.83
$7.48

Immunitybio Inc Stock (IBRX) Company Profile

Name
명칭
Immunitybio Inc
Name
전화
(844) 696-5235
Name
주소
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
직원
671
Name
트위터
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
IBRX's Discussions on Twitter

IBRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
IBRX
Immunitybio Inc
3.01 2.64B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-20 업그레이드 Piper Sandler Neutral → Overweight
2025-03-06 개시 H.C. Wainwright Buy
2025-01-10 개시 BTIG Research Buy
2023-05-12 다운그레이드 Piper Sandler Overweight → Neutral
2022-08-03 개시 Jefferies Buy

Immunitybio Inc 주식(IBRX)의 최신 뉴스

pulisher
12:27 PM

ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency - MSN

12:27 PM
pulisher
Jul 23, 2025

What analysts say about ImmunityBio Inc. stockHigh-yield market plays - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives ImmunityBio Inc. stock priceConsistently high yield - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is ImmunityBio Inc. a good long term investmentGame-changing returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga

Jul 22, 2025
pulisher
Jul 21, 2025

ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha

Jul 21, 2025
pulisher
Jul 20, 2025

ImmunityBio Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 15, 2025

ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView

Jul 15, 2025
pulisher
Jul 14, 2025

ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView

Jul 14, 2025
pulisher
Jul 12, 2025

ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha

Jul 12, 2025
pulisher
Jul 11, 2025

ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks

Jul 11, 2025
pulisher
Jul 10, 2025

Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN

Jul 10, 2025
pulisher
Jul 09, 2025

ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

ImmunityBio: D. Boral Capital Maintains Buy, Raises PT to $30 from $30 - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN

Jul 08, 2025
pulisher
Jul 07, 2025

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard

Jul 07, 2025
pulisher
Jul 07, 2025

ImmunityBio's ANKTIVA® Secures UK Approval: A Catalyst for Global Oncology Leadership - AInvest

Jul 07, 2025
pulisher
Jul 07, 2025

Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire

Jul 07, 2025
pulisher
Jul 07, 2025

ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView

Jul 07, 2025
pulisher
Jul 06, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 06, 2025
pulisher
Jul 04, 2025

UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication - MarketScreener

Jul 04, 2025
pulisher
Jul 02, 2025

ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success - Insider Monkey

Jul 02, 2025
pulisher
Jun 24, 2025

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

Anktiva Approved For Additional Treatment - Los Angeles Business Journal

Jun 23, 2025
pulisher
Jun 20, 2025

ImmunityBio Approves 2025 Equity Incentive Plan - TipRanks

Jun 20, 2025
pulisher
Jun 17, 2025

ImmunityBio's $10.5M Investor Deal Gets Final OK - Law360

Jun 17, 2025
pulisher
Jun 17, 2025

ImmunityBio Gets Final OK for $10.5 Million Investor Settlement - Bloomberg Law News

Jun 17, 2025
pulisher
Jun 12, 2025

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment - pharmaphorum

Jun 12, 2025
pulisher
Jun 12, 2025

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - newswire.ca

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze (NASDAQ:IBRX) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion - MSN

Jun 12, 2025
pulisher
Jun 08, 2025

15 Stocks That Stole The Show Last Week - Insider Monkey

Jun 08, 2025
pulisher
Jun 06, 2025

Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView

Jun 06, 2025
pulisher
Jun 05, 2025

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

H.C. Wainwright maintains buy rating on ImmunityBio stock after FDA milestones - Investing.com Nigeria

Jun 04, 2025
pulisher
Jun 04, 2025

ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwr - GuruFocus

Jun 04, 2025

Immunitybio Inc (IBRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
자본화:     |  볼륨(24시간):